Background
==========

Dysfunction of the immune system is evident in human immunodeficiency virus (HIV)-patients, even from the early phase of the HIV infection. The highly active antiretroviral therapy (HAART) dramatically affects the course of HIV-infection \[[@B1],[@B2]\], because it induces a significant immunological improvement associated with suppression of viral load (VL) \[[@B3],[@B4]\]. Most of HIV-patients on HAART are able to recover \"normal\" CD4^+^T-cell counts (\>500 cells/μl), and a substantial increase in naïve CD4^+^and recent thymic emigrants expressing T-cell receptor excision circles (TREC) has been reported \[[@B5],[@B6]\].

Immune recovery after HAART has been explained by either peripheral expansion of pre-existent naïve T cells, by recovery of new T cells derived from thymic production or by reversion from memory (CD45RO^+^) to naïve (CD45RA ^hi+^CD27^+^) phenotype of peripheral T cells \[[@B7]\]. IL-7 is very important in CD4+ recovery because it is implicated in thymopoiesis, peripheral T-cell expansion and survival of T cells. \[[@B8]\]. We carried out a cross-sectional study on HIV-patients (adults and children), who had recovered normal CD4^+^T-cell counts after HAART, grouped according to their previous clinical and immunological status to assess the different profiles of immune reconstitution.

Methods
=======

Study population
----------------

We carried out a cross-sectional study on HIV-patients (adults and children) grouped according to their previous clinical and immunological status. HIV-children were recruited in the Immuno-pediatric Unit (Hospital General Universitario \"Gregorio Marañón\", Madrid, Spain), and all children had been infected by vertical transmission. HIV-adults were recruited in Internal Medicine Unit (Hospital Universitario \"Virgen del Rocio\", Seville, Spain) with the following risk groups: 6 Intravenous drug users, 2 Heterosexuals, 1 Homosexual.

HIV patients, adults and children, were selected based on the following criteria: a) CD4^+^/μL greater than 500 cells/μL; b) HIV-RNA levels below detectable limits (VL ≤400 copies/ml) at least during 6 months before the study; c) prior diagnosis of AIDS but currently asymptomatic; d) on HAART at least during 6 months before the study. Also, healthy individuals (Healthy-adults and Healthy-children) were included in the study.

This study was conducted according to the declaration of Helsinki and approved by the Ethical Committees of all hospitals involved. Written informed consent was obtained from HIV-adults and the parents/guardians of children.

Drugs were prescribed by attending physicians according to Centers for Disease Control and Prevention (CDC) guidelines \[[@B9]\]. Clinical classification was based on the 1994 revised guidelines of the CDC \[[@B10]\]. The analyses of phenotypic subsets, TRECs and IL-7 quantification were carried out in a central laboratory (Laboratorio de Immuno-Biología Molecular, Hospital General Universitario \"Gregorio Marañón\") using standard procedures.

Quantification of HIV-1 RNA and IL-7 in plasma
----------------------------------------------

Blood samples were collected in EDTA tubes, separated within 4 h and the plasma was stored at -70°C. Plasma VL was quantified by Amplicor standard assay (Amplicor monitor, Roche Diagnostic Systems, Brandenburg, NJ, USA). Quantification of IL-7 levels was performed in duplicate using a ELISA assay kit (Quantikine HS IL-7 kit; R&D Systems, Abingdon, UK) \[[@B5]\].

Quantification of lymphocyte subsets
------------------------------------

Lymphocyte subsets were analyzed by four-color multiparametric flow cytometry. First, the blood was lysed with ImmunoPrep™ Reagent System (Beckman-Coulter, Inc; Fullerton, CA, USA) in a Coulter^®^TQ-Prep™ Workstation (Coulter Corporation, Miami, FL, USA). Then, the lymphocyte acquisition was carried out in a COULTER^®^EPICS^®^XL™ Flow Cytometer from Beckman-Coulter (Coulter Corporation) using the EXPO™32 ADC Software (Coulter Corporation) acquisition program immediately after cell staining \[[@B11]\]. Data were analyzed using the EXPO™32 ADC Software (Coulter Corporation) program. CYTO-COMP^®^cell kit, CYTO-COMP^®^reagent kit, and IMMUNOTROL^®^were routinely used as quality controls. The monoclonal antibodies used for the analyses of lymphocyte subsets were conjugated with Fluorescein-isothyocyanate (FITC) (anti-CD45, anti-CD45RA), Phycoerytrin (PE) (anti-CD27, anti-CD4), Phycoerytrin-Texas Red^®^-x (ECD) (anti-CD8), and R-Phycoerytrin-cyanin 5.1 (PC5) (anti-CD3, anti-CD4, anti-CD8). Anti-CD27-FITC, anti-CD4-PC5, and anti-CD8-PC5 were obtained from Immunotech (Marseille, France), and anti-CD45RA-PE from Southern Biotechnology Associates (Birmingham, AL, USA). The rest of the monoclonal antibodies were obtained from Cyto-Stat^®^Tetra-chrome™ (Coulter Corporation).

Quantification of TCR rearrangement excision circles
----------------------------------------------------

Thymic function was studied by quantifying the production of TRECs in peripheral blood mononuclear cells (PBMC) by real-time quantitative PCR in a LightCycler system (Roche Molecular Biochemicals, Mannheim, Germany) \[[@B5]\]. Samples were analyzed in triplicate and they never varied more than 10%. A β-globin control PCR was performed to verify the presence of the same content of DNA in all samples.

Statistical analysis
--------------------

The immunological values of HIV-adults and HIV-children (Xi) were transformed to Z-scores (*Z*- *score*= $\frac{\left( {Xi - \overline{X}} \right)}{\sigma}$) using the mean ($\overline{X}$) and standard deviation (σ) of Healthy-adults and Healthy-children respectively to unify value scales between children and adults to make them comparable. We calculated the differences between groups using the Mann-Whitney test.

Results
=======

Characteristics of HIV-1-infected patients
------------------------------------------

The HIV-patients were 9 HIV-Rec-adults (median (min; max): 40.8 (34.6; 43.7) years) and 10 HIV-Rec-children (median (min; max): 9.5 (7.1; 16.8) years) on HAART who had viral load (VL) ≤400 copies/ml and CD4+ ≥500 cells/μL at least 6 months prior to the study. Moreover, all patients had CD4+ ≤300 cells/μL and a diagnosis of AIDS at some point. These patients were compared with 15 Healthy-adults (median (min; max): 28.2 (26.3; 36.5) years) and 20 Healthy-children (median (min; max): 11.4 (6.3; 17.6) years). At the time of the study, HIV-Rec-adults and HIV-Rec-children had VL ≤400 copies/ml.

Markers of immune reconstitution
--------------------------------

HIV-Rec-children had lower CD4^+^counts (absolute and percentage) and higher %CD8^+^than Healthy-control, but HIV-Rec-adults had no statistical differences in CD4^+^absolute counts (Table [1](#T1){ref-type="table"}). HIV-Rec-children did not have higher CD4^+^absolute counts than HIV-Rec-adults (p = 0.072). However, when we analyzed the Z-score values, startlingly, we found that HIV-Rec-children had lower CD4^+^/μl Z-score values than HIV-Rec-adults (Table [2](#T2){ref-type="table"}).

###### 

Summary of immunological parameters of HIV patients and HIV-seronegative individuals for the cross-sectional study.

                          **HIV-Rec-adults**   **Healthy-adults**   ^**(*a*)**^***p***   **HIV-Rec-children**   **Healthy-children**   ^**(*b*)**^***p***   ^**(*c*)**^***p***
  ----------------------- -------------------- -------------------- -------------------- ---------------------- ---------------------- -------------------- --------------------
  ***No. of subjects***   9                    15                                        10                     20                                          
  ***T cells***                                                                                                                                             
   CD4^+^(%)              33.7 (25.9; 42.3)    42 (29.3; 56.6)      0.035                30.5 (18.1; 39.98)     42.3 (29.5; 55.4)      0.001                0.193
   CD8^+^(%)              36.2 (25.7; 53.5)    22.7 (16.1; 32.3)    \<0.001              38.6 (24.1; 63.9)      22.3 (13.6; 28.1)      \<0.001              1
   CD4^+^/μl              675 (563; 922)       864 (524; 1265)      0.815                837.5 (631; 1111)      1288 (588; 2804)       0.016                0.072
   CD8^+^/μl              881 (632; 1765)      492 (196; 878)       \<0.001              1038.5 (444; 2726)     673 (304; 1641)        0.091                0.620
  ***Thymic function***                                                                                                                                     
  TRECs/10^5^PBMC         25 (10; 106)         247 (10; 865)        0.006                10186 (1430; 18026)    16097 (5944; 43620)    0.082                \<0.001
  IL-7 (pg/ml)            5.5 (2.9; 11.2)      4.3 (2.4; 7.5)       0.015                2.2 (0.8; 7.14)        0.6 (0.3; 1.8)         0.001                0.002

Values are expressed as median (minimum; maximum). TREC: TCR rearrangement excision circles. Differences were calculated by U-test of Mann-Whitney.

(a): p-values between HIV-Rec-adults and Healthy-adults.

(b): p-values between HIV-Rec-children and Healthy-children.

(c): p-values between HIV-Rec-adults and HIV-Rec-children.

###### 

Summary of Z-scores of immunological markers in HIV patients for the cross-sectional study.

                             **HIV-Rec-adults**     **HIV-Rec-children**   ***p***
  -------------------------- ---------------------- ---------------------- ---------------
  ***T cells***                                                            
   CD4^+^(%)                 -0.83 (-2.29; -0.01)   -1.56 (-3.32; -0.24)   0.079
   CD8^+^(%)                 2.03 (0.53; 5.62)      3.99 (0.38; 10.28)     0.497
   CD4^+^/μl                 -0.05 (-0.61; 0.43)    -0.88 (-1.2; -0.47)    **\<*0.001***
   CD8^+^/μl                 2.12 (0.81; 7.54)      0.75 (-0.93; 5.5)      *0.053*
  ***Thymic function***                                                    
  TRECs/10^5^PBMC            -1.10 (-1.15; -0.83)   -0.74 (-1.43; -0.12)   ***0.036***
  IL-7 (pg/ml)               0.73 (-1.05; 4.62)     2.71 (-0.06; 12.8)     0.356
  ***T-cell subsets (%)***                                                 
  CD4^+^CD45RA^hi+^CD27^+^   -0.39 (-2.07; 0.7)     -0.61 (-3.17; 0.48)    0.400
  CD8^+^CD45RA^hi+^CD27^+^   -1.36 (-2.52; -0.25)   -2.52 (-4.63; 0.02)    *0.053*
  CD4^+^CD45RO^+^            0.95 (-1.1; 3.92)      0.06 (-2.08; 5.55)     0.243
  CD8^+^CD45RO^+^            1.48 (-0.38; 6.42)     2.43 (-0.28; 5.89)     0.780
  ***T-cell subsets/μl***                                                  
  CD4^+^CD45RA^hi+^CD27^+^   -0.34 (-1.42; 0.62)    -0.89 (-1.23; -0.39)   0.243
  CD8^+^CD45RA^hi+^CD27^+^   -0.45 (-0.9; 1.38)     -0.49 (-1.09; 0.92)    0.842
  CD4^+^CD45RO^+^            -0.03 (-0.64; 0.52)    -0.54 (-1.1; 0.97)     0.095
  CD8^+^CD45RO^+^            2.58 (0.61; 12.8)      1.01 (-0.5; 10.39)     0.315

Values are expressed as median (minimum; maximum). Differences were calculated by U-test of Mann-Whitney. p: p-values between HIV-Rec-adults and HIV-Rec-children.

Interestingly, HIV-Rec-adults had lower TREC values and higher IL-7 levels than healthy-adults, but HIV-Rec-children had similar TREC values and higher IL-7 levels than healthy-children (Table [1](#T1){ref-type="table"}). Moreover, we observed that HIV-Rec-children had higher TREC and lower IL-7 levels than HIV-Rec-adults (Table [1](#T1){ref-type="table"}). When we compared the Z-score values of HIV-Rec-adults and HIV-Rec-children, we found that HIV-Rec-children had similar IL-7 and higher TREC Z-score values than HIV-Rec-adults (Table [2](#T2){ref-type="table"}).

HIV-patients had similar naïve %CD4^+^and lower naïve %CD8^+^than Healthy-controls (Table [3](#T3){ref-type="table"}). However, when we analyzed the absolute counts, we found that HIV-Rec-children had lower naïve CD4^+^than Healthy-control but similar naïve CD8+. Moreover, HIV-Rec-children had higher naïve CD4^+^percentages and absolute counts, and higher naïve CD8^+^absolute counts than HIV-Rec-adults, but similar naïve CD8^+^percentages (Table [3](#T3){ref-type="table"}).

###### 

Summary of T-cell subsets of HIV patients and HIV-seronegative individuals for the cross-sectional study.

                             **HIV-Rec-adults**     **Healthy-adults**   ^**(*a*)**^***p***   **HIV-Rec-children**   **Healthy-children**   ^**(*b*)**^***p***   ^**(*c*)**^***p***
  -------------------------- ---------------------- -------------------- -------------------- ---------------------- ---------------------- -------------------- --------------------
  ***T-cell subsets (%)***                                                                                                                                       
  CD4^+^CD45RA^hi+^CD27^+^   36.8 (15.57; 51.86)    45.2 (16.5; 61.1)    0.263                56.4 (30.5; 67.4)      61.9 (45.9; 77.7)      0.080                0.009
  CD8^+^CD45RA^hi+^CD27^+^   26.61 (9.82; 62.3)     41.5 (27.5; 76.8)    0.001                38.1 (15.3; 65.8)      68.9 (44; 82.7)        0.001                0.107
  CD4^+^CD45RO^+^            51.2 (27.8; 85)        40.4 (21; 66.7)      0.048                41.2 (21; 92.5)        39.2 (24.8; 55.5)      0.683                0.243
  CD8^+^CD45RO^+^            27.4 (11.7; 69.4)      11.3 (3.4; 32.5)     0.007                52.1 (30; 80.3)        30.2 (20.4; 48.6)      0.002                0.133
  ***T-cell subsets/μl***                                                                                                                                        
  CD4^+^CD45RA^hi+^CD27^+^   296.8 (79.1; 493.5)    279 (172; 868.3)     0.263                445 (264; 716.6)       743.4 (289; 2062)      0.004                0.005
  CD8^+^CD45RA^hi+^CD27^+^   172.6 (96.8; 519.5)    164.1 (94; 524.4)    0.861                390 (225; 777.4)       463 (156; 1005)        0.495                0.002
  CD4^+^CD45RO^+^            351.8 (238.5; 453.6)   298.5 (171; 833.8)   0.682                374.8 (182.8; 894.8)   515.4 (151; 1368.6)    0.203                0.780
  CD8^+^CD45RO^+^            184.2 (96.4; 640.2)    64.3 (18; 162.7)     \<0.001              413.5 (153.; 2019.1)   183.7 (67; 691.6)      0.006                0.043

Values are expressed as median (minimum; maximum). Differences were calculated by U-test of Mann-Whitney.

(a): p-values between HIV-Rec-adults and Healthy-adults.

(b): p-values between HIV-Rec-children and Healthy-children.

(c): p-values between HIV-Rec-adults and HIV-Rec-children.

Regarding memory subsets, overall, HIV-patients had similar memory CD4^+^counts as Healthy-control; but when we analyzed memory CD8^+^, we found that HIV-patients had higher counts than Healthy-control (Table [3](#T3){ref-type="table"}). Furthermore, HIV-Rec-children had similar memory CD4^+^percentage and absolute counts, similar memory CD8^+^percentage and higher memory CD8^+^absolute counts than HIV-Rec-adults (Table [3](#T3){ref-type="table"}). Moreover, HIV-Rec-children had lower naïve CD8^+^Z-score values than HIV-Rec-adults (p = 0.055).

Discussion
==========

In humans, it is well established that HIV-1 infection adversely affects the thymus in both children and adults \[[@B7],[@B12]\]. However, a recent study showed that long term survivors of paediatric HIV infection appear to have retained or recovered thymic volume and thymic activity approximating uninfected youths \[[@B13]\]. Yet the consequences of this thymic inhibition are worse in children, which has been proposed as one cause of the rapid progression of the disease \[[@B14]-[@B16]\]. Early ART in HIV-infected children has proven to induce an early immune reconstitution that correlates with the increase in thymus volume \[[@B17]\]. ART has also proven to be effective in recovering appropriate CD4^+^levels in HIV-infected patients with low CD4^+^counts \[[@B5],[@B18]-[@B21]\], possibly through the production of new T cells in the thymus. This is particularly relevant for children, who have a smaller T-cell pool and thus rely more heavily upon thymic output for the generation of immune-competent memory T cells.

In this study, we observed that HIV-infected patients have lower thymic production than healthy controls. This inhibitory effect on the thymus may be due to the ability of HIV to infect and destroy thymocytes \[[@B22]\]. This would decrease the thymic production of new T cells and hinder both the appropriate maturation of the child\'s immune system and the reconstitution of cells lost due to the infection. When the thymic function of these HIV+ children on ART is analysed by the assessment of TRECs, it can be seen that the decrease in the viral load leads to a marked rise in thymic function \[[@B23],[@B24]\], and it correlates well with the recovery of CD4^+^T-cell population \[[@B5],[@B6],[@B24]-[@B26]\].

In this study, we analyzed, as a whole, different aspects of immunity in HIV-1 infected patients on HAART with a previous moderate to severe immunosuppression state and who had been able to recover \"normal\" CD4^+^T-cell counts (\>500 cells/μl). Interestingly, HIV-Rec-adults had lower TREC Z-score levels than HIV-Rec-children. Therefore, our results contribute new findings and extend the previous data indicating that T-cell reconstitution in HIV-adults is mainly thymus-independent \[[@B7]\]. However, HIV-Rec-adults had detectable TREC levels, although lower than healthy-adults, indicating their thymus was somewhat functional \[[@B11],[@B27]\]. In addition, HIV-adults had naïve CD4^+^and CD8^+^counts too high to be explained by the low TREC values observed in peripheral blood. The HIV-adults could still have a defective immune system despite normal recovery of CD4^+^counts, although we cannot determine this since we do not have data on their TCR repertoire. Furthermore, HIV-children had a mainly thymus-dependent immune reconstitution \[[@B5],[@B28]\]. Thymic function of HIV-Rec-children had a greater capacity for recovery during severe HIV-infection, and they seemed to be less affected than the HIV-Rec-adults when TREC Z-score values were compared.

Interestingly, HIV-infected patients have abnormally high plasma levels of IL-7 associated with low counts of CD4^+^\[[@B29]\]. This suggests that low CD4^+^counts should stimulate peripheral dendritic cells and lymphatic ganglia to produce IL-7, in an attempt to activate the mechanisms that allow cell repopulation \[[@B29]\]. By contrast, other studies have suggested that plasma IL-7 levels may simply reflect the dynamics of binding secreted IL-7 to T cells: the fewer circulating T cells, the greater amount of free IL-7 \[[@B30]\]. However, these high levels of IL-7 are ineffective in adults since no increase in thymic production or recuperation of the CD4^+^T-cell repertoire has been observed, possibly due to the limited ability of the adult thymus to produce new T cells.

Thus, better thymic function in HIV-children may allow for the maintaining of a high output of naïve T cells resulting in lower IL-7 levels \[[@B31]\]. In contrast, the thymus of HIV-adults generated less naïve T cells, making it necessary for more IL-7 to generate T cells by antigen-independent peripheral expansion \[[@B7],[@B27]\]. Therefore, the high values of IL-7 could be considered normal in HIV-adults and their immune reconstitution via stimulation T cell peripheral expansion may be more IL-7-dependent. However, a role of the thymus cannot be discarded in immune reconstitution in HIV-adults.

In our experience, high levels of IL-7 in children with lower CD4^+^counts lead to a dramatic increase in the thymic production of new T cells and a marked recovery of CD4^+^counts \[[@B5]\]. This increase in thymic function takes place whenever viral load levels are low enough. Then, with the recovery of CD4+ counts, IL-7 returns to basal values as a consequence of a feedback mechanism \[[@B5]\].

Among HIV-children, we found that the thymic function of HIV-Rec-children appears to be normal, although it is well-known that HIV-infection could produce irreversible injury to the thymus of HIV-patients with AIDS \[[@B7]\]. However, high IL-7 values in HIV-Rec-children could increase the thymic output, increasing TRECs values and compensating for the faulty thymic function. It is also possible that IL-7 stimulates the production of T cells by antigen-independent peripheral expansion \[[@B7]\]. It is unclear why HIV-patients had a deficient *de novo*generation of CD4^+^but not of CD8^+^. Extrathymic CD8^+^but not CD4^+^lymphopoiesis has been documented in mice, which if extrapolated to humans could partially explain those differences \[[@B32],[@B33]\]. Alternatively, this finding could be explained by elevated peripheral proliferation of naïve CD4^+^and CD8^+^\[[@B34]\].

A limitation of the study could be that immunological recovery was dependent on sustained VL suppression and efficacy of antiretrovirals that contribute to the HAART regimen. In this study, the size of groups was very small and we could not make strata according to antiretroviral therapy and sustained VL suppression periods to check the possible effect of these two factors. Another limitation of our study was that there was a difference between the age of healthy adults of the control group and HIV-Rec-adults. However, we think this difference has a low impact on the TREC levels in adults, since all of the subjects were adults inside an age range of approximately 25--40 years, Harris et al \[[@B35]\] in a previous study showed that thymic abundance was not inversely correlated with age in HIV-infected adults and the variation in the 25--40 year-old range is minimal.

Conclusion
==========

In summary, HIV-Rec-children had better thymic function than HIV-Rec-adults which affects the composition of peripheral T-cell subsets. So, T-cell recovery after HAART in HIV-Rec-adults could be the consequence of antigen-independent peripheral expansion, while neolymphopoiesis in the thymus of HIV-Rec-children could play an important role in immune reconstitution. Therefore, HIV-patients with similar CD4^+^counts could have CD4^+^of different origins and function.

Abbreviations
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**CD4**^**+**^**CD45RA**^**hi+**^**CD27**^**+**^Naïve CD4^+^T-cells

**CD4**^**+**^**CD45RO**^**+**^Memory CD4^+^T-cells

**CD8**^**+**^**CD45RA**^**hi+**^**CD27**^**+**^Naïve CD8^+^T-cells

**CD8**^**+**^**CD45RO**^**+**^Memory CD8^+^T-cells

**CDC**Centers for Disease Control and Prevention

**HAART**Highly active antiretroviral therapy

**Healthy-adults**Healthy age-matched uninfected adults as controls.

**Healthy-children**Healthy age-matched uninfected children as controls.

**HIV-Rec-adults**HIV-adults in clinical category C and CD4^+^T-cell ≤300 cells/μL anytime before who responded to the treatment recovering CD4^+^T-cell \>500 cells/μL after HAART.

**HIV-Rec-children**HIV-children in clinical category C and CD4^+^T-cell ≤300 cells/μL anytime before who responded to the treatment recovering CD4^+^T-cell \>500 cells/μL after HAART.

**IL**Interleukin

**PBMC**Peripheral blood mononuclear cells

**TREC**T-cell receptor excision circles

**VL**Viral load

**Z-scores***Z*- *score*= $\frac{\left( {Xi - \overline{X}} \right)}{\sigma}$ using the mean ($\overline{X}$), standard deviation (σ), and values of HIV-adults and HIV-children (Xi)
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